The pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market has grown rapidly in recent years. It will grow from $39.8 billion in 2023 to $46.29 billion in 2024 at a compound annual growth rate (CAGR) of 16.3%. The growth observed in the historical period can be primarily attributed to several key factors. Among these are significant advancements in immunotherapy, marked by notable progress in clinical success rates and subsequent approvals. Moreover, the increased incidence of cancer has also contributed significantly to this growth trajectory. Additionally, a notable shift in the treatment paradigm for cancer, marked by a greater emphasis on innovative approaches such as immunotherapy, has played a pivotal role. Collaborations within the industry and substantial investments in research have further propelled advancements in cancer treatment, contributing significantly to the overall growth observed during this period.
The pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market is expected to see rapid growth in the next few years. It will grow to $80.1 billion in 2028 at a compound annual growth rate (CAGR) of 14.7%. Anticipated growth in the forecast period stems from various factors, notably the expansion of indications for treatments, heightened focus on biomarker research, and the advent of personalized medicine. The prognosis is also influenced by increased engagement in clinical trials and research collaborations, alongside ongoing development in global healthcare infrastructure.
The projected growth in the PD-1 and PD-L1 Inhibitors, also known as Immune Checkpoint Inhibitors, market is heavily influenced by the escalating prevalence of cancer cases. Cancer, characterized by uncontrolled cell growth and dissemination, has seen a noticeable increase in cases over recent years. PD-1 and PD-L1 inhibitors play a crucial role in treating cancer by leveraging the body's immune system to combat cancer cells effectively. For example, as per the European Union Science Hub's findings in October 2023, the preceding two years witnessed a 2.3% rise in new cancer cases, reaching 2.74 million, alongside a 2.4% increase in cancer-related deaths. This surge in cancer incidence significantly contributes to the growth anticipated in the PD-1 and PD-L1 Inhibitors market.
The anticipated growth in the PD-1 and PD-L1 Inhibitors market is closely tied to the increasing emphasis on personalized medicine. This advanced healthcare approach considers unique patient factors such as genetics, behaviors, and environmental influences in treatment strategies. In the context of PD-1 and PD-L1 inhibitors, personalized medicine involves tailoring cancer therapies to optimize efficacy and minimize potential adverse effects based on individual patient characteristics and biomarker expressions. Notably, the Personalized Medicine Coalition's data from February 2023 revealed that personalized medications accounted for 34% of newly approved pharmaceuticals by the US FDA in 2022, showcasing a sustained upward trend. This growing focus on personalized medicine significantly drives the PD-1 and PD-L1 Inhibitors market forward.
Product innovation has emerged as a pivotal trend shaping the landscape of PD-1 and PD-L1 Inhibitors, or immune checkpoint inhibitors. Leading market players are strategically channeling efforts towards developing innovative products to bolster their market presence. For instance, Bristol-Myers Squibb's successful FDA approval for Opdualag in March 2022 marked a breakthrough - a fixed-dose combination of nivolumab (Opdivo) and relatlimab, the latter being a LAG-3 inhibitor. Opdualag, the first LAG-3 inhibitor approved by the US FDA for treating metastatic melanoma, aims to augment immune responses against cancer cells, showcasing a substantial leap in product innovation within this sector.
Strategic investments play a crucial role in shaping the landscape of the PD-1 and PD-L1 Inhibitors market. Major companies operating in this domain are leveraging strategic initiatives to fortify their positions. For instance, Regeneron Pharmaceuticals, Inc.'s investment in June 2022 involved acquiring Sanofi's share in the Regeneron and Sanofi partnership concerning Libtayo (cemiplimab). This strategic move conferred Regeneron exclusive rights to develop, market, and manufacture Libtayo globally. Valued at $900 million, plus royalties and potential future milestone payments, this investment aimed to bolster Regeneron's foothold in the market. Libtayo, a first-in-class PD-1 inhibitor developed using Regeneron's VelocImmune technology, gained approval from the FDA and numerous global regulatory bodies, solidifying its position as a standard treatment for certain advanced non-small cell lung cancer, cutaneous squamous cell carcinoma, and basal cell carcinoma cases.
In January 2021, Biond Biologics, an Israel-based clinical-stage biopharmaceutical firm, forged a strategic partnership with Sanofi AG, a leading pharmaceutical and healthcare company headquartered in France. The primary objective of this alliance revolves around advancing the development and commercialization of BND-22, a pioneering immune checkpoint inhibitor designed specifically to target the ILT2 receptor. This collaborative venture strongly resonates with Biond's overarching strategy of cultivating impactful partnerships with prominent entities within the biopharmaceutical realm. By synergizing the collective expertise and resources of both entities, this collaboration is poised to deliver substantial value for shareholders while advancing the potential of BND-22 in the market.
Major companies operating in the pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market report are Bristol-Myers Squibb Company, Merck and Company, F. Hoffmann-La Roche AG, Sanofi S.A., Amgen Inc., Gilead Sciences Inc., AstraZeneca plc, Novartis AG, Pfizer Inc., GlaxoSmithKline Plc, Regeneron Pharmaceuticals Inc., BeiGene Ltd., Shanghai Jhunsi Biosciences Ltd., Akeso Inc., Alphamab Oncology, Eli Lilly and Company, Boehringer Ingelheim, Xencor Inc., Taiga Biotechnologies Inc., Jiangsu Alphamab Biopharmaceuticals Co. Ltd., Dr. Reddy's Laboratories Ltd., Laekna Therapeutics, Genentech Inc., Tracon Pharmaceuticals Inc., Celgene, Hangzhou Sumgen Co. Ltd., Agenus Inc., BioNTech SE, Celldex Therapeutics Inc., CytomX Therapeutics Inc.
North America was the largest region in the PD-1 and PDL1 inhibitors market in 2023. The regions covered in the pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Key products within the PD-1 and PDL1 inhibitor category include nivolumab, pembrolizumab, atezolizumab, avelumab, and durvalumab. Nivolumab, specifically a PD-1 inhibitor, operates by impeding the PD-1 receptor present on T cells, thereby thwarting cancer cells' ability to evade immune system attacks. These inhibitors find application in treating a spectrum of cancers such as lung cancer, bladder cancer, melanoma, Hodgkin lymphoma, colorectal cancer, among others.
These immunotherapy drugs are available through various channels including hospital pharmacies, retail pharmacies, and online platforms. They are predominantly utilized within hospital settings, specialty clinics, as well as academic and research institutions, constituting integral elements in comprehensive cancer care and research endeavors.
The PD-1 and PDL1 Inhibitors/ Immune checkpoint inhibitors market consists of sales of various inhibitors such as cemiplimab, sintilimab, and camrelizumab. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market is expected to see rapid growth in the next few years. It will grow to $80.1 billion in 2028 at a compound annual growth rate (CAGR) of 14.7%. Anticipated growth in the forecast period stems from various factors, notably the expansion of indications for treatments, heightened focus on biomarker research, and the advent of personalized medicine. The prognosis is also influenced by increased engagement in clinical trials and research collaborations, alongside ongoing development in global healthcare infrastructure.
The projected growth in the PD-1 and PD-L1 Inhibitors, also known as Immune Checkpoint Inhibitors, market is heavily influenced by the escalating prevalence of cancer cases. Cancer, characterized by uncontrolled cell growth and dissemination, has seen a noticeable increase in cases over recent years. PD-1 and PD-L1 inhibitors play a crucial role in treating cancer by leveraging the body's immune system to combat cancer cells effectively. For example, as per the European Union Science Hub's findings in October 2023, the preceding two years witnessed a 2.3% rise in new cancer cases, reaching 2.74 million, alongside a 2.4% increase in cancer-related deaths. This surge in cancer incidence significantly contributes to the growth anticipated in the PD-1 and PD-L1 Inhibitors market.
The anticipated growth in the PD-1 and PD-L1 Inhibitors market is closely tied to the increasing emphasis on personalized medicine. This advanced healthcare approach considers unique patient factors such as genetics, behaviors, and environmental influences in treatment strategies. In the context of PD-1 and PD-L1 inhibitors, personalized medicine involves tailoring cancer therapies to optimize efficacy and minimize potential adverse effects based on individual patient characteristics and biomarker expressions. Notably, the Personalized Medicine Coalition's data from February 2023 revealed that personalized medications accounted for 34% of newly approved pharmaceuticals by the US FDA in 2022, showcasing a sustained upward trend. This growing focus on personalized medicine significantly drives the PD-1 and PD-L1 Inhibitors market forward.
Product innovation has emerged as a pivotal trend shaping the landscape of PD-1 and PD-L1 Inhibitors, or immune checkpoint inhibitors. Leading market players are strategically channeling efforts towards developing innovative products to bolster their market presence. For instance, Bristol-Myers Squibb's successful FDA approval for Opdualag in March 2022 marked a breakthrough - a fixed-dose combination of nivolumab (Opdivo) and relatlimab, the latter being a LAG-3 inhibitor. Opdualag, the first LAG-3 inhibitor approved by the US FDA for treating metastatic melanoma, aims to augment immune responses against cancer cells, showcasing a substantial leap in product innovation within this sector.
Strategic investments play a crucial role in shaping the landscape of the PD-1 and PD-L1 Inhibitors market. Major companies operating in this domain are leveraging strategic initiatives to fortify their positions. For instance, Regeneron Pharmaceuticals, Inc.'s investment in June 2022 involved acquiring Sanofi's share in the Regeneron and Sanofi partnership concerning Libtayo (cemiplimab). This strategic move conferred Regeneron exclusive rights to develop, market, and manufacture Libtayo globally. Valued at $900 million, plus royalties and potential future milestone payments, this investment aimed to bolster Regeneron's foothold in the market. Libtayo, a first-in-class PD-1 inhibitor developed using Regeneron's VelocImmune technology, gained approval from the FDA and numerous global regulatory bodies, solidifying its position as a standard treatment for certain advanced non-small cell lung cancer, cutaneous squamous cell carcinoma, and basal cell carcinoma cases.
In January 2021, Biond Biologics, an Israel-based clinical-stage biopharmaceutical firm, forged a strategic partnership with Sanofi AG, a leading pharmaceutical and healthcare company headquartered in France. The primary objective of this alliance revolves around advancing the development and commercialization of BND-22, a pioneering immune checkpoint inhibitor designed specifically to target the ILT2 receptor. This collaborative venture strongly resonates with Biond's overarching strategy of cultivating impactful partnerships with prominent entities within the biopharmaceutical realm. By synergizing the collective expertise and resources of both entities, this collaboration is poised to deliver substantial value for shareholders while advancing the potential of BND-22 in the market.
Major companies operating in the pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market report are Bristol-Myers Squibb Company, Merck and Company, F. Hoffmann-La Roche AG, Sanofi S.A., Amgen Inc., Gilead Sciences Inc., AstraZeneca plc, Novartis AG, Pfizer Inc., GlaxoSmithKline Plc, Regeneron Pharmaceuticals Inc., BeiGene Ltd., Shanghai Jhunsi Biosciences Ltd., Akeso Inc., Alphamab Oncology, Eli Lilly and Company, Boehringer Ingelheim, Xencor Inc., Taiga Biotechnologies Inc., Jiangsu Alphamab Biopharmaceuticals Co. Ltd., Dr. Reddy's Laboratories Ltd., Laekna Therapeutics, Genentech Inc., Tracon Pharmaceuticals Inc., Celgene, Hangzhou Sumgen Co. Ltd., Agenus Inc., BioNTech SE, Celldex Therapeutics Inc., CytomX Therapeutics Inc.
North America was the largest region in the PD-1 and PDL1 inhibitors market in 2023. The regions covered in the pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Key products within the PD-1 and PDL1 inhibitor category include nivolumab, pembrolizumab, atezolizumab, avelumab, and durvalumab. Nivolumab, specifically a PD-1 inhibitor, operates by impeding the PD-1 receptor present on T cells, thereby thwarting cancer cells' ability to evade immune system attacks. These inhibitors find application in treating a spectrum of cancers such as lung cancer, bladder cancer, melanoma, Hodgkin lymphoma, colorectal cancer, among others.
These immunotherapy drugs are available through various channels including hospital pharmacies, retail pharmacies, and online platforms. They are predominantly utilized within hospital settings, specialty clinics, as well as academic and research institutions, constituting integral elements in comprehensive cancer care and research endeavors.
The PD-1 and PDL1 Inhibitors/ Immune checkpoint inhibitors market consists of sales of various inhibitors such as cemiplimab, sintilimab, and camrelizumab. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Characteristics3. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Trends and Strategies31. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Competitive Benchmarking32. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Competitive Dashboard33. Key Mergers and Acquisitions in the PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market
4. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market - Macro Economic Scenario
5. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Size and Growth
6. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Segmentation
7. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Regional and Country Analysis
8. Asia-Pacific PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market
9. China PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market
10. India PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market
11. Japan PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market
12. Australia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market
13. Indonesia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market
14. South Korea PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market
15. Western Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market
16. UK PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market
17. Germany PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market
18. France PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market
19. Italy PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market
20. Spain PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market
21. Eastern Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market
22. Russia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market
23. North America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market
24. USA PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market
25. Canada PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market
26. South America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market
27. Brazil PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market
28. Middle East PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market
29. Africa PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market
30. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Competitive Landscape and Company Profiles
34. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Future Outlook and Potential Analysis
35. Appendix
Executive Summary
This report provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
Scope
Markets Covered:1) By Product: Nivolumab; Pembrolizumab; Atezolizumab; Avelumab; Durvalumab
2) By Distribution Channel: Hospital pharmacies; Retail pharmacies; Online pharmacies
3) By Application: Lung Cancer; Bladder Cancer; Melanoma; Hodgkin Lymphoma; Colorectal Cancer; Other Applications
4) By End-Users : Hospitals; Specialty Clinics; Academic and Research Institutions
Companies Mentioned: Bristol-Myers Squibb Company; Merck and Company; F. Hoffmann-La Roche AG; Sanofi S.A.; Amgen Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bristol-Myers Squibb Company
- Merck and Company
- F. Hoffmann-La Roche AG
- Sanofi S.A.
- Amgen Inc.
- Gilead Sciences Inc.
- AstraZeneca plc
- Novartis AG
- Pfizer Inc.
- GlaxoSmithKline Plc
- Regeneron Pharmaceuticals Inc.
- BeiGene Ltd
- Shanghai Jhunsi Biosciences Ltd.
- Akeso Inc.
- Alphamab Oncology
- Eli Lilly and Company
- Boehringer Ingelheim
- Xencor Inc.
- Taiga Biotechnologies Inc.
- Jiangsu Alphamab Biopharmaceuticals Co. Ltd
- Dr. Reddy's Laboratories Ltd.
- Laekna Therapeutics
- Genentech Inc.
- Tracon Pharmaceuticals Inc.
- Celgene
- Hangzhou Sumgen Co. Ltd
- Agenus Inc.
- BioNTech SE
- Celldex Therapeutics Inc.
- CytomX Therapeutics Inc.
Methodology
LOADING...
